New hope for deadly seizures: experimental drug SAGE-547 tested
NCT ID NCT02433314
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study offered SAGE-547, an experimental drug given as a continuous IV infusion, to people aged 6 months and older with super-refractory status epilepticus—a dangerous condition where seizures continue despite standard treatments. The goal was to see if the drug could help control these seizures. The study is no longer available for enrollment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAGE-547 injection
- What this could lead to
- If it works, this could provide a new treatment option for people with super-refractory status epilepticus, a life-threatening seizure condition that doesn't respond to standard medications.
- What could go wrong
- This is an expanded access program, not a controlled trial, so results are limited. The drug may not work for everyone, and side effects are possible. The study is no longer available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUPER-REFRACTORY STATUS EPILEPTICUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.